RMC-4630 (SAR442720) is an SHP2 inhibitor under phase I/II trial that evaluates the safety, MTD, and RP2D of RMC-4630 in combination with cobimetinib in patients with relapsed/refractory solid tumors and combination with osimertinib in patients with EGFR-mutant locally advanced or metastatic NSCLC (NCT04000529). Here, EGFR is linked to non-small cell lung carcinoma.